ARCA biopharma (NASDAQ:ABIO) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of ARCA biopharma (NASDAQ:ABIO) in a research report released on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

ARCA biopharma Trading Up 0.3 %

ABIO opened at $3.25 on Wednesday. The stock has a market capitalization of $47.15 million, a PE ratio of -7.74 and a beta of 0.89. ARCA biopharma has a 1-year low of $1.56 and a 1-year high of $4.49. The firm has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $2.12.

ARCA biopharma (NASDAQ:ABIO) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ARCA biopharma stock. abrdn plc bought a new stake in ARCA biopharma, Inc. (NASDAQ:ABIO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 32,461 shares of the biopharmaceutical company’s stock, valued at approximately $55,000. Institutional investors own 56.44% of the company’s stock.

ARCA biopharma Company Profile

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.